Clinical Trials on Recurrent Uveal Melanoma

Total 10155 results

National Cancer Institute (NCI)

Completed

Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA Melanoma

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
National Cancer Institute (NCI)

Completed

Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF

Liver Metastases | Uveal Melanoma

United States
Gradalis, Inc.

Completed

Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma

Melanoma | Malignant Melanoma | Melanoma Recurrent

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); National Comprehensive Cancer Network

Completed

Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations

Recurrent Melanoma | Stage IV Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
Memorial Sloan Kettering Cancer Center
United States Department of Defense

Completed

Clinical and Histopathologic Characteristics of BAP1 Mutations

Renal Cell Carcinoma | Cholangiocarcinoma | Malignant Pleural Mesothelioma (MPM) | Choroidal Nevus | Primary Uveal Melanoma (UM) | Metastatic Uveal Melanoma (UM)

United States
National Cancer Institute (NCI)

Terminated

Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV

Recurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma

United States
Charite University, Berlin, Germany

Unknown

TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy

Uveal Melanoma | Exudative Retinal Detachment

Germany
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations

Recurrent Melanoma | Stage IV Melanoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
Fred Hutchinson Cancer Center

Completed

Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Terminated

A Phase II Study of UCN-01 in Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Completed

Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Completed

Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Terminated

Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Completed

BMS-247550 in Treating Patients With Stage IV Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Completed

Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
Institut Curie

Active, not recruiting

Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR)

Triple Negative Breast Cancer | Pediatric Cancer | Metastatic Uveal Melanoma | Luminal B Breast Cancer

France
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Acral Lentiginous Malignant Melanoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
National Cancer Institute, Naples

Completed

Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma (SICOG 0109)

Recurrent Melanoma | Malignant Melanoma
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma

Recurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IA Melanoma | Stage IB Melanoma | Stage IIA Melanoma

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Completed

Viral Therapy in Treating Patients With Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Completed

Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Completed

Tipifarnib in Treating Patients With Metastatic Malignant Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Terminated

SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Completed

Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer | Stage III Melanoma

United States
National Cancer Institute (NCI)

Completed

Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma

United States
Erasmus Medical Center
Ludwig Institute for Cancer Research; Dutch Cancer Society; Stichting Coolsingel... and other collaborators

Recruiting

MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer (MC2TCR)

Melanoma | Head and Neck Cancer | Melanoma, Uveal

Netherlands
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study

Melanoma | Metastatic Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Recurrent Metastatic Melanoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Completed

PS-341 in Treating Patients With Metastatic Malignant Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
Fred Hutchinson Cancer Research Center/University...
National Cancer Institute (NCI)

Completed

Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
University of Washington
National Cancer Institute (NCI)

Terminated

Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma

United States
National Cancer Institute (NCI)

Terminated

Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma

United States
National Cancer Institute (NCI)

Completed

Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA Melanoma

United States
Eric Bernicker, MD

Terminated

Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma (ENSIGN)

Nonsquamous Nonsmall Cell Neoplasm of Lung | Metastatic Uveal Melanoma | Lung Squamous Cell Carcinoma Stage IV

United States
Stanford University
National Cancer Institute (NCI)

Completed

Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant Melanoma

Recurrent Melanoma

United States
Zai Lab (Shanghai) Co., Ltd.

Terminated

A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma

Unresectable, Recurrent or Metastatic Melanoma | Untreated Mucosal or Acral Lentiginous Melanoma

China
Shields, Shields and Associates

Unknown

Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy

Uveal Melanoma | Radiation Retinopathy | Radiation Maculopathy

United States
National Cancer Institute (NCI)

Terminated

Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery

Unspecified Adult Solid Tumor, Protocol Specific | Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); National Comprehensive Cancer Network

Terminated

Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery

Recurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma (Locally Advanced) | Stage IIC Melanoma (Locally Advanced) | Stage IV Melanoma (Limited, Resectable)

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers

Unspecified Adult Solid Tumor, Protocol Specific | Recurrent Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
Kari Kendra
Karyopharm Therapeutics Inc

Completed

Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery (KPT-330)

Recurrent Melanoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma

Recurrent Melanoma

United States
Case Comprehensive Cancer Center

Completed

Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance

Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Recurrent Intraocular Melanoma

United States

Clinical Trials on Recurrent Uveal Melanoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations